Heplisav-B Versus Engerix-B in Adults 60-70 Years of Age: HBV-23 Diabetes Mellitus Subgroup Analysis
Study comparing Heplisav-B and Engerix-B vaccines in adults aged 60-70 with type 2 diabetes mellitus, showing higher seroprotection with Heplisav-B. Detailed results, subpopulation analysis, and conclusions are presented.
Uploaded on Apr 15, 2025 | 0 Views
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Heplisav-B versus Engerix-B in Adults 60-70 Years of Age HBV-23 (Diabetes Mellitus Subgroup Analysis)
Heplisav-B Vaccine versus Engerix-B Vaccine in Adults 60-70 Years of Age HBV-23 DM Subgroup Analysis: Study Design Background - To assess the immunogenicity of Heplisav-B (HBsAg-1018) vaccine versus alum-adjuvanted Engerix-B vaccine in adults 60-70 years of age with type 2 diabetes mellitus in a pre- specified subgroup analysis of HBV-23 Participants - n = 480 persons with type 2 diabetes mellitus - Ages: 60-70 years - HBV vaccine na ve - Exclusions: HBV*, HIV, pregnancy (or lactation), chronic steroid use, autoimmune condition Study Primary End-Point - Seroprotection = anti-HBs antibody level 10 mIU/mL *Any positive for HBsAg, anti-HBs, or anti-HB core Source: Hyer RN, Janssen RS. Vaccine. 2019:37:5854-61.
Heplisav-B Vaccine versus Engerix-B Vaccine in Adults 60-70 Years of Age HBV-23 DM Subgroup Analysis: Results Heplisav-B Engerix-B 100 Seroprotective Response Rate (%) P <0.001 P <0.001 85.8 85.4 80 60 58.5 57.7 40 20 0 Per-Protocol Modified Intent-to-Treat Source: Hyer RN, Janssen RS. Vaccine. 2019:37:5854-61.
Heplisav-B Vaccine versus Engerix-B Vaccine in Adults 60-70 Years of Age HBV-23 DM Subgroup Analysis: Subpopulations Heplisav-B Engerix-B 83.9 Male 57.5 89.0 Female 59.6 82.8 Obese 52.7 92.7 Non-obese 71.8 81.6 Smoker 47.1 86.7 Non-smoker 60.2 0 20 40 60 80 100 Seroprotection Rates (%) Source: Hyer RN, Janssen RS. Vaccine. 2019:37:5854-61.
Heplisav-B Vaccine versus Engerix-B Vaccine in Adults 60-70 Years of Age HBV-23 DM Subgroup Analysis: Conclusions Conclusions: Two doses of HBsAg/CpG 1018 provides a higher level of seroprotection against HBV than does a 3-dose vaccine (HBsAg/alum) with a similar safety profile in patients aged 60- 70 years with type 2 diabetes mellitus. Source: Hyer RN, Janssen RS. Vaccine. 2019:37:5854-61.
This slide deck is from the University of Washingtons Hepatitis B Online and Hepatitis C Online projects. Hepatitis B Online www.hepatitisB.uw.edu Hepatitis C Online www.hepatitisC.uw.edu This project is funded by the Centers for Disease Control and Prevention (CDC) Cooperative Agreement (CDC-RFA- PS21-2105)
